

Discussion points: During the development of the ISCTM Workshop publication “Biomarkers for Drug Development in Early Psychosis: Current Issues and Promising Directions” a crucial gap in the literature was identified. Very few studies compare multiple biomarkers and the methodology used across studies is rarely comparable therefore meaningful comparisons are not possible. Another hundred biomarkers studies without addressing these deficiencies will be of limited value.

Potential solution is the design of an ADNI-like prospective study with the working title “Schizophrenia ADNI” that includes academia, industry, federal and foundation input and support. The Biomarkers committee will discuss potential designs and logistics for such a study.